Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8318-8324

  Freytes, Cesar O ^a,b   Ratanatharathorn, Voravit ^c   Taylor, Charles ^d   Abboud, Camille ^e   Chesser, Nancy ^f   Restrepo, Alejandro ^a,b   Arango, Jorge ^a   Odenheimer, Daniel ^f  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; MELPHALAN; PLACEBO; REPIFERMIN; THIOTEPA;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BONE MARROW PURGING; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTORS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PLACEBOS; SAFETY; STOMATITIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 11144235534     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1118     Document Type: Article

References (18)

1. Chapko MK, Syrjala KL, Schilter L, et al. Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea. Bone Marrow Transplant 1989;4:181-6.
2. McGuire DB, Altomonte V, Peterson DE, et al. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum 1993;20:1493-502.
3. Sonis ST. Oral complication of cancer therapy. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th ed. Philadelphia: JB Lippincott; 1993. p. 2385-9.
4. Sonis ST, Sonis AL, Lieberman A. Oral complications in patients receiving treatment for malignancies other than of the head and neck. J Am Dent Assoc 1978;97:468-72.
5. Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer (Phila) 1993;72:1612-7.
6. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998;34:39-43.
7. Emoto H, Tagashira S, Mattei MG, et al. Structure and expression of human fibroblast growth factor-10. J Biol Chem 1997;272:23191-4.
8. Finch PW, Rubin JS, Miki T, et al. Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science (Wash DC) 1989;245:752-5.
9. Lu W, Luo Y, Kan M, McKeehan WL. Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 1999;274:12827-34.
10. Han DS, Li F, Holt L, et al. Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats. Am J Physiol Gastrointest Liver Physiol 2000;279:G1011-22.
11. Sung C, Parry TJ, Riccobene TA, et al. Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans. AAPS PharmSci [serial on the Internet]. 2002 [cited 2003 22 Jan];4:[article 8, 10 screens]. Available from: URL:/www.aapspharmsci.org.
12. Miceli R, Hubert M, Santiago G, et al. Efficacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis. J Pharmacol Exp Ther 1999;290:464-71.
13. Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 1998;92:3960-7.
14. Alderson R, Gohari-Fritsch S, Olsen H, et al. In vitro and in vivo effects of repifermin (keratinocyte growth factor-2, KGF-2) on human carcinoma cells. Cancer Chemother Pharmacol 2002;50:202-12.
15. Freytes C, LeVeque F, Meisenberg B, et al. Safety and efficacy of repifermin (KGF-2) in reducing mucositis in patients undergoing autologous hematopoietic stem cell transplantation (auto-HSCT)-results of a phase 2a trial [abstract 5154]. Blood 2001;98:346b.
16. Sonis ST, Eilers JP, Epstein JB, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer (Phila) 1999;85:2103-13.
17. Spielberger R, Emmanouilides C, Stiff P, et al. Use of recombinant human keratinocyte growth factor (rHuKGF) can reduce severe oral mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning-results of a phase 3 trial. Presented at the Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3,2003. Available from http://www.asco.org/ac/l,1003,_12-002643-00_18-0023-00_19-00200005,00.asp.
18. Bellm LA, Epstein JB, Rose-Ped A, et al. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000;8:33-9.